ATXI - AVENUE THERAPEUTICS, INC.

0.42
-0.432   -102.881%

Share volume: 1,156,557
Last Updated: 03-18-2025
Pharmaceutical Products/Pharmaceutical Preparations: 0.05%

PREVIOUS CLOSE
CHG
CHG%
$0.85
-0.43
-0.51%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
22%
Profitability 0%
Dept financing 9%
Liquidity 50%
Performance 40%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
0   0%
1 Month
-59.20%
3 Months
-76.81%
6 Months
-78.79%
1 Year
185.91%
2 Year
-99.54%
Key data
Stock price
$0.42
P/E Ratio 
0.00
DAY RANGE
$0.39 - $0.55
EPS 
-$23.31
52 WEEK RANGE
$0.09 - $8.99
52 WEEK CHANGE
$180.75
MARKET CAP 
3.564 M
YIELD 
N/A
SHARES OUTSTANDING 
1.431 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
04-15-2025
BETA 
0.33
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
N/A
AVERAGE 30 VOLUME 
$244,456
Company detail
CEO: Alexandra MacLean
Region: US
Website: avenuetx.com
Employees: 4
IPO year: 2017
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Avenue Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, a synthetic dual-acting opioid, which is in Phase III clinical trials for the treatment of post-operative acute pain.

Recent news
loading